880
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
 patients with multiple myeloma: Subject; Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen: Treatment; multiple myeloma: Treatment.Disorder; bortezomib: Treatment.Drug; lenalidomide/: Treatment.Drug; dexamethasone: Treatment.Drug; bortezomib: Treatment.Drug; dexamethasone: Treatment.Drug; bortezomib: Combination.Drug; lenalidomide/: Combination.Drug; dexamethasone: Combination.Drug; bortezomib: Combination.Drug; dexamethasone: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients with multiple myeloma: Subject; Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen: Treatment; multiple myeloma: Treatment.Disorder; bortezomib: Treatment.Drug; lenalidomide/: Treatment.Drug; dexamethasone: Treatment.Drug; bortezomib: Treatment.Drug; dexamethasone: Treatment.Drug; bortezomib: Combination.Drug; lenalidomide/: Combination.Drug; dexamethasone: Combination.Drug; bortezomib: Combination.Drug; dexamethasone: Combination.Drug